Oncoimmunology
Journal
Overview
publication venue for
-
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases..
12.
2023
-
A mitochondrial checkpoint to adaptive anticancer immunity..
12.
2023
-
CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response..
12.
2023
-
Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis..
11.
2022
-
Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses..
11.
2022
-
A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients..
11.
2022
-
Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling..
11.
2022
-
Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes..
11.
2022
-
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells..
10.
2021
-
Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy..
10.
2021
-
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma..
10.
2021
-
A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy..
10.
2021
-
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients..
10.
2021
-
Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer..
9.
2020
-
Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade..
9.
2020
-
Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide..
9.
2020
-
Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response..
9.
2020
-
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models..
9.
2020
-
Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy..
9.
2020
-
Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery..
8.
2019
-
Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients..
8.
2019
-
Apoptotic caspases cut down the immunogenicity of radiation..
8.
2019
-
Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion..
8.
2019
-
Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody..
8.
2019
-
Metabolic enzymes expressed by cancer cells impact the immune infiltrate..
8.
2019
-
Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer..
8.
2019
-
Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells..
8.
2019
-
Anticancer effects of anti-CD47 immunotherapy in vivo..
8.
2018
-
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model..
8.
2018
-
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer..
7.
2018
-
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab..
7.
2018
-
Immune effectors responsible for the elimination of hyperploid cancer cells..
7.
2018
-
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study..
7.
2018
-
CD4+ Th1 to the rescue in HER-2+ breast cancer..
8.
2018
-
Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer..
7.
2018
-
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms..
7.
2018
-
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial..
7.
2017
-
Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival..
6.
2017
-
Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages..
6.
2017
-
Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2..
6.
2017
-
Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling..
6.
2017
-
Novel immune checkpoint blocker to treat Merkel cell carcinoma..
6.
2017
-
Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant..
6.
2017
-
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody..
6.
2017
-
Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer..
6.
2016
-
CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy..
6.
2016
-
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules..
6.
2016
-
Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics..
5.
2016
-
IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay..
5.
2016
-
Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy..
5.
2016
-
The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ..
5.
2016
-
Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity..
5.
2016
-
Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer..
6.
2016
-
IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression..
6.
2016
-
Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors..
5.
2016
-
Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy..
5.
2016
-
Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer..
5.
2016
-
First oncolytic virus approved for melanoma immunotherapy..
5.
2015
-
Doubling the blockade for melanoma immunotherapy..
5.
2015
-
Targeting abnormal ER stress responses in tumors: A new approach to cancer immunotherapy..
5.
2015
-
Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)..
4.
2015
-
Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark..
4.
2015
-
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study..
4.
2015
-
Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody..
4.
2015
-
Genetics and immunology: reinvigorated..
4.
2015
-
Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells..
4.
2015
-
Trial watch: Naked and vectored DNA-based anticancer vaccines..
4.
2015
-
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers..
4.
2015
-
Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma..
4.
2015
-
Immune independent crosstalk between lymphoma and myeloid suppressor CD14+HLA-DRlow/neg monocytes mediates chemotherapy resistance..
4.
2015
-
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo..
4.
2015
-
Novel immune checkpoint blocker approved for the treatment of advanced melanoma..
3.
2014
-
The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer..
3.
2014
-
Vitamin B6 improves the immunogenicity of cisplatin-induced cell death..
3.
2014
-
Trial Watch: Toll-like receptor agonists in oncological indications..
3.
2014
-
Trial watch: Immunostimulatory cytokines in cancer therapy..
3.
2014
-
Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy..
3.
2014
-
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death..
3.
2014
-
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set..
3.
2014
-
Is tumor (R)ejection by the immune system the "5th R" of radiobiology?.
3.
2014
-
Detection of cancer/testis antigens as a diagnostic tool in routine pathology practice..
3.
2014
-
Novel insights into the mechanism of action of lenalidomide..
3.
2014
-
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy..
3.
2014
-
Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy..
3.
2014
-
Immunological effects of chemotherapy in spontaneous breast cancers..
2.
2013
-
Immune effectors required for the therapeutic activity of vorinostat..
2.
2013
-
Immunogenic cell death in radiation therapy..
2.
2013
-
The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer..
2.
2013
-
Current trends of anticancer immunochemotherapy..
2.
2013
-
Prognostic value of the immune microenvironment in lung adenocarcinoma..
2.
2013
-
Trial Watch: Adoptive cell transfer for anticancer immunotherapy..
2.
2013
-
Approaching untargetable tumor-associated antigens with antibodies..
2.
2013
-
Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy..
2.
2013
-
ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy..
2.
2013
-
Trial watch: Oncolytic viruses for cancer therapy..
2.
2013
-
Cancer immunotherapy turns viral..
2.
2013
-
Trial watch: DNA vaccines for cancer therapy..
2.
2013
-
Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma..
2.
2013
-
Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment..
2.
2013
-
Novel multifunctional antibody approved for the treatment of breast cancer..
2.
2013
-
Trial watch: Chemotherapy with immunogenic cell death inducers..
2.
2013
-
Utilizing TH9 cells as a novel therapeutic strategy for malignancies..
2.
2013
-
Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy..
2.
2013
-
Rejuvenated T cells attack old tumors..
2.
2013
-
Trial watch: Cardiac glycosides and cancer therapy..
2.
2013
-
An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells..
2.
2013
-
Trial watch: Monoclonal antibodies in cancer therapy..
2.
2013
-
Victories and deceptions in tumor immunology: Stimuvax®.
2.
2013
-
Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects..
1.
2012
-
How do CARs work?: Early insights from recent clinical studies targeting CD19..
1.
2012
-
Trial watch: Peptide vaccines in cancer therapy..
1.
2012
-
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer..
1.
2012
-
Trial watch: Dendritic cell-based interventions for cancer therapy..
1.
2012
-
"Flagellated" cancer cells propel anti-tumor immunity..
1.
2012
-
Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles..
1.
2012
-
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy..
1.
2012
-
DKK1 as a novel target for myeloma immunotherapy..
1.
2012
-
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy..
1.
2012
-
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo..
1.
2012
-
Trial Watch: Immunostimulatory cytokines..
1.
2012
-
Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer..
1.
2012
-
Trial Watch: Adoptive cell transfer immunotherapy..
1.
2012
-
Trial watch: Chemotherapy with immunogenic cell death inducers..
1.
2012
-
Trial Watch: Monoclonal antibodies in cancer therapy..
1.
2012
-
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence..
11.
2022
-
Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents..
10.
2021
-
NK cells beat T cells at early breast cancer control..
9.
2020
-
Mitochondrial control of innate immune signaling by irradiated cancer cells..
9.
2020
-
Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients..
8.
2019
-
Potent immunosuppressive effects of the oncometabolite R-2-hydroxyglutarate..
7.
2018
-
CARs on a highway with roadblocks..
6.
2017
-
Blinatumomab bridges the gap between leukemia and immunity..
6.
2017
-
CD103+ cells at the forefront of anticancer immunity..
6.
2017
-
Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade..
6.
2017
-
PD-L1 blockade for urothelial carcinoma..
6.
2017
-
Calreticulin and type I interferon: An unsuspected connection..
6.
2017
-
Immunosuppressive γδ T cells foster pancreatic carcinogenesis..
5.
2016
-
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?.
4.
2015
-
New immunotherapeutic paradigms for castration-resistant prostate cancer..
2.
2013
-
Activin A backs-up TGF-ß to promote regulatory T cells.
2021
-
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.
2020
-
IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection.
2020
-
Trial watch: STING agonists in cancer therapy.
2020
-
Trial watch: IDO inhibitors in cancer therapy.
2020
-
Trial watch: TLR3 agonists in cancer therapy.
2020
-
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
2020
-
Trial watch: dendritic cell vaccination for cancer immunotherapy.
2019
-
Trial watch: dietary interventions for cancer therapy.
2019
-
Trial Watch: Toll-like receptor agonists in cancer immunotherapy.
2018
-
Trial watch: Peptide-based vaccines in anticancer therapy.
2018
-
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
2018
-
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.
2018
-
Trial watch: DNA-based vaccines for oncological indications.
2017
-
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.
2017
-
Trial watch: Immune checkpoint blockers for cancer therapy.
2017
-
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
2017
-
Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
2017
-
Trial Watch: Immunotherapy plus radiation therapy for oncological indications.
2016
-
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.
2016
-
Prioritization schema for immunotherapy clinical trials in glioblastoma.
2016
-
Trial Watch-Immunostimulation with cytokines in cancer therapy.
2015
-
Trial Watch-Oncolytic viruses and cancer therapy.
2015
-
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.
2015
-
T cell receptor mimic antibodies for cancer therapy.
2015
-
Trial Watch: Adoptive cell transfer for oncological indications.
2015
-
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
2015
-
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
2015
-
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.
2015
-
Trial Watch: Peptide-based anticancer vaccines.
2015
-
Trial watch: Dendritic cell-based anticancer therapy.
2014
-
Trial watch: IDO inhibitors in cancer therapy.
2014
-
Consensus guidelines for the detection of immunogenic cell death.
2014
-
Trial Watch: Radioimmunotherapy for oncological indications.
2014
-
Trial Watch:: Oncolytic viruses for cancer therapy.
2014
-
Trial Watch: Adoptive cell transfer for anticancer immunotherapy.
2014
-
Trial Watch: DNA vaccines for cancer therapy.
2014
-
Trial Watch: Chemotherapy with immunogenic cell death inducers.
2014
-
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.
2014
-
Trial Watch: Peptide vaccines in cancer therapy.
2013
-
Trial Watch: Lenalidomide-based immunochemotherapy.
2013
-
Trial watch: Dendritic cell-based interventions for cancer therapy.
2013
-
Trial Watch: Anticancer radioimmunotherapy.
2013
-
Trial Watch: Toll-like receptor agonists for cancer therapy.
2013
-
Trial Watch: Immunostimulatory cytokines.
2013
-
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
2023
-
Trial watch: intratumoral immunotherapy.
2021
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)